These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 22068656)

  • 21. A pilot trial of a carcinoembryonic antigen/ TRICOM-based vaccine and radiation to liver metastases in patients with carcinoembryonic antigen-positive solid tumors.
    Ahlers CM; Camphausen K; Citrin D; Arlen PM; Gulley JL
    Clin Colorectal Cancer; 2006 May; 6(1):72-5. PubMed ID: 16796796
    [No Abstract]   [Full Text] [Related]  

  • 22. Synergy of vaccine strategies to amplify antigen-specific immune responses and antitumor effects.
    Grosenbach DW; Barrientos JC; Schlom J; Hodge JW
    Cancer Res; 2001 Jun; 61(11):4497-505. PubMed ID: 11389081
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial.
    Antonilli M; Rahimi H; Visconti V; Napoletano C; Ruscito I; Zizzari IG; Caponnetto S; Barchiesi G; Iadarola R; Pierelli L; Rughetti A; Bellati F; Panici PB; Nuti M
    Int J Oncol; 2016 Apr; 48(4):1369-78. PubMed ID: 26892612
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical evaluation of TRICOM vector therapeutic cancer vaccines.
    Madan RA; Bilusic M; Heery C; Schlom J; Gulley JL
    Semin Oncol; 2012 Jun; 39(3):296-304. PubMed ID: 22595052
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study in cancer patients of a replication-defective avipox recombinant vaccine that expresses human carcinoembryonic antigen.
    Marshall JL; Hawkins MJ; Tsang KY; Richmond E; Pedicano JE; Zhu MZ; Schlom J
    J Clin Oncol; 1999 Jan; 17(1):332-7. PubMed ID: 10458251
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intratumoral vaccination and diversified subcutaneous/ intratumoral vaccination with recombinant poxviruses encoding a tumor antigen and multiple costimulatory molecules.
    Kudo-Saito C; Schlom J; Hodge JW
    Clin Cancer Res; 2004 Feb; 10(3):1090-9. PubMed ID: 14871989
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Phase I Dose-Escalation Trial of BN-CV301, a Recombinant Poxviral Vaccine Targeting MUC1 and CEA with Costimulatory Molecules.
    Gatti-Mays ME; Strauss J; Donahue RN; Palena C; Del Rivero J; Redman JM; Madan RA; Marté JL; Cordes LM; Lamping E; Orpia A; Burmeister A; Wagner E; Pico Navarro C; Heery CR; Schlom J; Gulley JL
    Clin Cancer Res; 2019 Aug; 25(16):4933-4944. PubMed ID: 31110074
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Development of the PANVAC-VF vaccine for pancreatic cancer.
    Petrulio CA; Kaufman HL
    Expert Rev Vaccines; 2006 Feb; 5(1):9-19. PubMed ID: 16451103
    [TBL] [Abstract][Full Text] [Related]  

  • 29. TRICOM: enhanced vaccines as anticancer therapy.
    Levy B; Panicalli D; Marshall J
    Expert Rev Vaccines; 2004 Aug; 3(4):397-402. PubMed ID: 15270644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
    Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tecemotide: an antigen-specific cancer immunotherapy.
    Wurz GT; Kao CJ; Wolf M; DeGregorio MW
    Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings.
    Oudard S; Rixe O; Beuselinck B; Linassier C; Banu E; Machiels JP; Baudard M; Ringeisen F; Velu T; Lefrere-Belda MA; Limacher JM; Fridman WH; Azizi M; Acres B; Tartour E
    Cancer Immunol Immunother; 2011 Feb; 60(2):261-71. PubMed ID: 21069322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I clinical trial of a recombinant canarypoxvirus (ALVAC) vaccine expressing human carcinoembryonic antigen and the B7.1 co-stimulatory molecule.
    Hörig H; Lee DS; Conkright W; Divito J; Hasson H; LaMare M; Rivera A; Park D; Tine J; Guito K; Tsang KW; Schlom J; Kaufman HL
    Cancer Immunol Immunother; 2000 Nov; 49(9):504-14. PubMed ID: 11092617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical and immune responses in advanced colorectal cancer patients treated with anti-idiotype monoclonal antibody vaccine that mimics the carcinoembryonic antigen.
    Foon KA; John WJ; Chakraborty M; Sherratt A; Garrison J; Flett M; Bhattacharya-Chatterjee M
    Clin Cancer Res; 1997 Aug; 3(8):1267-76. PubMed ID: 9815809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified vaccinia virus ankara recombinants are as potent as vaccinia recombinants in diversified prime and boost vaccine regimens to elicit therapeutic antitumor responses.
    Hodge JW; Poole DJ; Aarts WM; Gómez Yafal A; Gritz L; Schlom J
    Cancer Res; 2003 Nov; 63(22):7942-9. PubMed ID: 14633725
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Vector-based vaccine/cytokine combination therapy to enhance induction of immune responses to a self-antigen and antitumor activity.
    Aarts WM; Schlom J; Hodge JW
    Cancer Res; 2002 Oct; 62(20):5770-7. PubMed ID: 12384537
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression.
    Gameiro SR; Higgins JP; Dreher MR; Woods DL; Reddy G; Wood BJ; Guha C; Hodge JW
    PLoS One; 2013; 8(7):e70417. PubMed ID: 23894654
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccine-based therapy directed against carcinoembryonic antigen demonstrates antitumor activity on spontaneous intestinal tumors in the absence of autoimmunity.
    Greiner JW; Zeytin H; Anver MR; Schlom J
    Cancer Res; 2002 Dec; 62(23):6944-51. PubMed ID: 12460911
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A feasibility study of cyclophosphamide, trastuzumab, and an allogeneic GM-CSF-secreting breast tumor vaccine for HER2+ metastatic breast cancer.
    Chen G; Gupta R; Petrik S; Laiko M; Leatherman JM; Asquith JM; Daphtary MM; Garrett-Mayer E; Davidson NE; Hirt K; Berg M; Uram JN; Dauses T; Fetting J; Duus EM; Atay-Rosenthal S; Ye X; Wolff AC; Stearns V; Jaffee EM; Emens LA
    Cancer Immunol Res; 2014 Oct; 2(10):949-61. PubMed ID: 25116755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An updated evaluation of serum sHER2, CA15.3, and CEA levels as biomarkers for the response of patients with metastatic breast cancer to trastuzumab-based therapies.
    Perrier A; Boelle PY; Chrétien Y; Gligorov J; Lotz JP; Brault D; Comperat E; Lefèvre G; Boissan M
    PLoS One; 2020; 15(1):e0227356. PubMed ID: 31910438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.